Across TCGA pan-cancer cohorts, CRACDL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CRACDL data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CRACDL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRACDL expression acts as an unfavorable survival marker, although some lineages such as CCRCC and OV show a favorable association.

HNSC, CCRCC, and OV are the cancer types where CRACDL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.509	0.762	.006	17	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	10	view →
OV	DFS	Median	All	0.922	0.630	.047	4	view →
LSCC	OS	Median	All	0.674	0.866	.010	4	view →
GBM	OS	Median	All	0.888	0.744	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CRACDL tumor-vs-normal RNA expression · all CRACDL data types